Back لاميفودين/زيدوفودين Arabic Lamivudina/zidovudina Spanish 라미부딘/지도부딘 Korean ଲାମିଭୁଡିନ/ଜିଡୋଭୁଡିନ OR Ламивудин/Зидовудин Russian Lamivudin/zidovudin Serbo-Croatian Lamivudin/zidovudin Serbian Зидовудин/Ламівудин Ukrainian Lamivudine/zidovudine Vietnamese 拉米夫定/齐多夫定 Chinese
 | |
| Combination of | |
|---|---|
| Lamivudine | Nucleoside analogue reverse transcriptase inhibitor |
| Zidovudine | Nucleoside analogue reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Combivir |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a601066 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| KEGG | |
| NIAID ChemDB | |
| CompTox Dashboard (EPA) | |
| (verify) | |
Lamivudine/zidovudine, sold under the brand name Combivir among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS.[2] It contains two antiretroviral medications, lamivudine and zidovudine.[2] It is used together with other antiretrovirals.[2] It is taken by mouth twice a day.[2][3]
Common side effects include headache, feeling tired, nausea, diarrhea, and fever.[3] Severe side effects may include bone marrow suppression, muscle damage, worsening of hepatitis B if previously infected, high blood lactate and liver enlargement.[2][4] It may be part of a recommended treatment during pregnancy.[2] The medications are both of the nucleoside reverse transcriptase inhibitor (NRTI) class.[2] They work by blocking the action of the enzyme, reverse transcriptase, that the virus requires to reproduce.[3]
Lamivudine/zidovudine was approved for medical use in the United States in 1997, and in the European Union in 1998.[3][5] It is on the World Health Organization's List of Essential Medicines.[6] It is available as a generic medication.[4]
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ a b c d e f g World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 157, 161. hdl:10665/44053. ISBN 9789241547659.
- ^ a b c d "Combivir- lamivudine and zidovudine tablet, film coated". DailyMed. 10 May 2019. Retrieved 29 May 2020.
- ^ a b Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 59. ISBN 9781284057560.
- ^ Cite error: The named reference
Combivir EPARwas invoked but never defined (see the help page). - ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.